Aripiprazole oral product

DRUG2 trials

Sponsors

Indiana University, Otsuka Pharmaceutical Co., Ltd.

Conditions

AutismPervasive Developmental Disorder

Phase 3

Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders

CompletedNCT00870727

Indiana UniversityPervasive Developmental Disorder

Start: 2009-02-28End: 2015-05-31Updated: 2019-01-02

Unknown Phase

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

CompletedNCT03179787

Otsuka Pharmaceutical Co., Ltd.Autism

Start: 2017-04-01End: 2020-07-06Updated: 2021-09-16

Related Papers

Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance.

2021-04-224 citations